Ketamine Is the New Viagra
A combination of high demand and a patent monopoly has created a perfect storm of profitability for Janssen’s Spravato.
generic drugs
-
Read more: Ketamine Is the New Viagra -
Read more: Fatty Acids, Skinny Labels: Fish Oil Patent Battle Back in Court Fatty Acids, Skinny Labels: Fish Oil Patent Battle Back in Court
An ongoing patent battle over omega-3 fatty acids may have broad implications for the marketing of generic drugs.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Topics range from issues related to FDA’s approval of aducanumab, to an analysis of the communication of survival data in cancer drug labels.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of June 2021.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of March 2021.
-
Read more: New Rule Might Increase Out-of-Pocket Drug Costs for Patients New Rule Might Increase Out-of-Pocket Drug Costs for Patients
Patients may face increased out-of-pocket drug costs as a result of a rule finalized by the Centers for Medicare & Medicaid Services in July 2020.
-
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: AbbVie Wins First Round in Humira Antitrust Lawsuit AbbVie Wins First Round in Humira Antitrust Lawsuit
The purpose of the secondary patent filings was to assemble a thicket of patents, 132 in all, to prohibit competition from biosimilar companies.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Selections feature topics ranging from political pressures facing the FDA, to the financial incentive structure for antibiotic development.
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on pharma, health law, and policy issues from August 2020.